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Introduction
Although the natural history of persistent HCV and HBV 
infections in humans is different, failure of T cell immu-
nity is a common feature. Many of the same defects in T 
cell immunity have been described in both infections. For 
instance, an absence of sustained virus-specific CD4+ 
helper T cell immunity is central to development of chronic 
HBV and HCV infection. Cytotoxic CD8+ T cells persist in 
the liver after chronic infections are established, but lack key 
effector functions, a state defined as exhaustion. Whether 
exhaustion can be reversed by vaccination and/or interfer-
ence with inhibitory signaling pathways that are active in 
exhausted CD8+ T cells is of current interest, especially 
for HBV where treatment options for long-term control of 
infection are limited. Some CD8+ T cell populations appear 
to be more exhausted than others during persistent virus 
infections, depending on whether viral class I epitopes have 
acquired mutations and evade recognition by CD8+ T cells. 
Substantial evidence supporting this concept has come from 
studies of HCV, a virus that is classified into seven differ-
ent genotypes and multiple subtypes that differ up to 20 % 
at the amino acid level. During recent years, comparison 
of large number of HCV sequences has provided detailed 
insight into intra-host evolution as well as sequence diver-
sity between hosts. Combined with studies of CD8+ T cell 
phenotype and function, it is now apparent that the response 
shapes viral evolution. In turn, HCV sequence diversity 
influences the quality of the CD8+ T cell response and thus 
infection outcome. Here, we review published studies of 
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CD8+ T cell selection pressure and mutational escape of 
the virus.
Evidence for CD8+ T cell selection pressure and HCV 
evolution
HCV particles harbor a positive-strand RNA genome that 
is directly translated in the cytosol of infected cells into 
a polyprotein approximately 3,000 amino acids in length. 
The polyprotein is cleaved by cellular and viral proteases 
into functional units. The virus encodes an RNA-depend-
ent RNA polymerase (RdRp) located at the C-terminal 
end of the polyprotein (NS5B) that is needed for RNA-
replication. Due to the lack of a proofreading function by 
the RdRp, viral replication is error prone and results in a 
swarm of multiple closely related but distinct viral variants 
termed as quasispecies. In response to selection pressure, 
viral variants that are best adapted for survival emerge 
from the quasispecies. It is now well established that 
CD8+ T cells are a significant source of selection pressure 
against HCV, most notably during the acute phase of infec-
tion. The CD8+ T cell response is highly individualized 
because multiple distinct allotypes with different epitope 
binding properties exist for HLA class I A, B and C genes. 
Transmission of the virus to a new host can therefore 
cause a dramatic shift in the epitope repertoire recognized 
by CD8+ T cells.
Evidence that HCV adapts to CD8+ T cell immune 
pressure by selection of substitutions in targeted 
epitopes was first obtained in the chimpanzee model 
[1, 2], which was well suited for these studies because 
viruses with a defined genome sequence could be used to 
initiate infection. Similar studies were subsequently car-
ried out in infected humans under circumstances where 
the genomic sequences of donor and recipient viruses 
were available for comparison [3, 4]. Analysis of virus 
evolution in the chimpanzees and humans revealed a 
much higher rate of non-synonymous mutation in class I 
epitopes when compared with other regions of the HCV 
genome not under selection pressure by CD8+ T cells. 
The most comprehensive human study was performed 
in a cohort of eight people who inject drugs (PWID) 
with acute HCV genotype 1a infection [5]. Approxi-
mately 50 % of the class I epitopes acquired non-synon-
ymous substitutions that facilitated escape from CD8+ 
T cell recognition. In turn, about 50 % of the substitu-
tions in the non-structural proteins were associated with 
a detectable CD8+ T cell response. Other studies of 
human subjects are consistent with these findings [6–9]. 
The impact of CD8+ T cells on virus evolution has also 
been examined by aligning HCV amino acid polymor-
phisms and patterns of HLA class I allele expression in 
large populations of HCV-infected patients. These analy-
ses provided additional evidence, even in the absence of 
donor virus genome sequences, that escape mutation is a 
very common and partially predictable feature of HCV 
infections that persist [10–13].
An increased rate of non-synonymous mutation in 
class I epitopes versus flanking regions was predomi-
nantly observed during the acute phase in human [6] 
and chimpanzee [14, 15] infections that ultimately per-
sisted. As an example, in chimpanzees infected with 
clonal HCV genomes, non-synonymous mutation in class 
I epitopes was highest during the first 8–12 months of 
infection [14], just before CD8+ T cell selection pres-
sure is thought to gradually fail. Once chronic infection 
was established, the rate of non-synonymous mutation is 
not substantially different between class I epitopes and 
flanking regions of the HCV genome. This suggests that 
the capacity of CD8+ T cells to recognize escape vari-
ants within epitopes, or to broaden to new epitopes, is 
limited during the chronic phase of infection. Consist-
ent with these observations, escape mutations in HCV 
epitopes that arise during the acute phase are usually 
stable through decades of chronic infection [9, 16, 17] 
and de novo responses against new epitopes are equally 
rare [18]. This is quite different from the situation in per-
sistent HIV infection where expansion of “escape-spe-
cific” CD8 T cells after selection of substitutions inside 
epitopes has been described [19, 20], most commonly for 
class I alleles such as HLA-B*27 and HLA-B*57 asso-
ciated with protection from disease progression [21–24]. 
The HIV-specific CD8+ T cell response can also further 
broaden over the course of infection [25, 26]. Why the 
HCV-specific CD8+ T cell response fails to keep pace 
with virus evolution or broaden to new epitopes is not 
known. It might be explained by the concept of origi-
nal antigenic sin, defined as impairment of a secondary 
immune response against a distinct but closely related 
antigen. This concept was described for CD8+ T cells 
in some murine models of virus infection [27], although 
it appears not to be universally operational in all set-
tings [28]. Failure of CD8+ T cells to recognize new or 
escaped HCV epitopes may coincide with the profound, 
but as yet unexplained absence of HCV-specific CD4+ T 
cells during chronic infection [29]. Loss of CD4+ T cell 
help during the acute phase of infection might facilitate 
the initial emergence of escape variants. In support of 
this concept, one study in chimpanzees documented that 
antibody-mediated depletion of CD4+ T cells facilitated 
epitope escape from CD8+ T cells [30]. Further research 
is needed, however, to determine how an absence of 
helper activity during the acute and chronic phases of 
infection contributes to virus evolution and the capacity 
of CD8+ T cells to exert selection pressure.
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Functional mechanisms underpinning escape of class I 
epitopes
Mutation of even a single amino acid within an HCV 
epitope can defeat CD8+ T cell recognition through mul-
tiple mechanisms. One dominant mechanism involves 
mutation of an epitope anchor residue required for binding 
to the MHC class I molecule. Suboptimal binding leads 
to an unstable MHC class I/peptide complex and loss of 
the epitope. This appears to be the most frequent mecha-
nism of immune escape for HIV because the majority of 
selected substitutions are located at these important anchor 
residues [31, 32]. Whether anchor residue substitutions are 
also the most common mechanism for mutational escape 
of HCV has not yet been determined. Amino acid substi-
tutions at non-anchor residues can also impair CD8+ T 
cell recognition if they are located at the interface of the 
T cell receptor (TcR) and MHC class I/peptide complex. 
In this case, the variant epitope is still presented by the 
MHC class I molecule, but TcR binding is impaired. In the 
chimpanzee model, there is evidence that this mechanism 
of mutational immune escape is associated with a narrow 
TcR repertoire, whereas a broader repertoire may prevent 
viral escape, possibly due to enhanced cross-reactivity 
with more sequence variants of the epitope [33]. This 
observation suggests that CD8+ T cell populations may be 
qualitatively different in their capacity of immune selec-
tion. The ability to recognize multiple variants of a class I 
epitope may be the most important during the acute phase 
of infection before effective CD4+ and CD8+ T cell 
immunity is lost.
Finally, selected amino acid substitutions may alter 
processing of CD8+ T cell epitopes. Antigen presentation 
is a multi-step process that requires proteasomal degrada-
tion of viral proteins, transport to the endoplasmic reticu-
lum, N-terminal trimming by amino peptidases and trans-
port of the stabilized MHC class I/peptide complex to the 
cell surface. Many of these steps are sequence dependent 
and variation inside or near the epitope could alter this 
process. For example, it has been shown that substitu-
tions inside the epitope can disrupt the endogenously 
processed epitope by preferential cleavage inside the 
epitope by the proteasome [34]. Altered epitope process-
ing was also associated with substitutions in the C-termi-
nal flanking region of an HLA-A*02-restricted epitope 
[35]. Whether such substitutions in the epitope flanking 
region are indeed selected by CD8+ T cell immune pres-
sure is less clear. We recently identified a substitution five 
amino acids upstream of an HLA-B*51-restricted epitope 
in NS3 that is significantly more frequent in HLA-B*51-
positive patients infected with HCV genotype 1a (unpub-
lished). Functional analysis revealed that this substitution 
impaired antigen processing supporting that selection of 
altered epitope processing contributes to CD8+ T cell 
immune escape, although the overall extent of this viral 
escape pathway is unclear in hepatitis C.
Relevance of CD8+ T cell escape mutations to infection 
outcome
Mutational escape of HIV from dominant CD8+ T cell 
responses is associated with increased replication of the 
persistent virus and progression to AIDS [36–38]. Whether 
escape mutations in class I epitopes determine whether 
acute HCV infection will ultimately resolve or persist is 
less clear. Viral mutational escape may simply be a con-
sequence of continuous viral replication in the presence 
of selection pressure and not causal for viral persistence. 
Studies in chimpanzees experimentally infected with well-
defined strains of the HCV revealed that class I escape 
mutations are much less common in infections that resolve 
spontaneously when compared with those that persist [2]. 
These studies are much more difficult to perform in humans 
because the acute phase of infection is often unrecognized 
due to mild or inapparent symptoms and the sequence of 
the donor virus is often not known. One study has none-
theless documented that escape mutations are also less 
frequent in acute resolving versus persistent HCV infec-
tions in humans [5]. Despite these associations, a convinc-
ing causal relationship between class I epitope escape and 
infection outcome has not been established. Such an analy-
sis is likely to be complicated by multiple factors includ-
ing the breadth of the CD8+ T cell response, whether viral 
fitness for replication is impaired by mutation of dominant 
epitopes, and the timing of CD4+ T cell loss and CD8+ T 
cell exhaustion during acute hepatitis C.
The impact of escape mutations and infection outcome 
is also likely to be influenced by HLA haplotype. Protec-
tive HLA class I alleles that correlate with better infec-
tion outcome have been identified for HIV [39] and HCV 
[40–42]. In HIV, there is evidence that immune control can 
be maintained despite selection of escape mutations in key 
epitopes presented by protective class I alleles like HLA-
B*27 and HLA-B*57 [23, 43–45]. These key epitopes 
are constrained from mutation because of excessive fit-
ness costs and selection of unfit viral variants may even be 
causal for viral containment [31, 46–48]. This would sug-
gest that viral constraints determine the protective effect 
of particular HLA class I alleles. On the other hand, it has 
been argued that the epitopes presented by protective HLA 
class I alleles are targeted by T cells with stronger or more 
sustained antiviral activity [49]. There are strong argu-
ments for both concepts, and successful control of infec-
tion might require a combination of both the “right” T cells 
against the “right” epitopes. It is notable that HLA-B*27 
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and HLA-B*57 are also associated with protection against 
HCV persistence. These two alleles, along with the protec-
tive allele HLA-A*03, present HCV epitopes that are none-
theless prone to mutational escape [50–52]. An important 
difference between these “protective” epitopes and “con-
ventional” epitopes presented by other alleles may again be 
the genetic barrier to resistance. Mutational escape of HCV 
is also associated with varying degrees of fitness cost [13, 
16, 17, 53]. Consequently, many escape mutations revert 
back to the prototype sequence in the absence of immune 
pressure [3, 54]. This has most recently been described 
in chronically infected pregnant women, where selection 
pressure is thought to be attenuated because of changes in 
maternal immunity to protect the fetus [55]. The genetic 
barrier to viral escape may be particularly high when the 
impact of mutation on virus replication is severe and/
or a complex pattern of multiple substitutions is required 
to achieve full immune escape, as shown for dominant 
HCV epitopes presented by protective alleles [51, 56–58]. 
For immune escape from the dominant HLA-A*03- and 
HLA-B*57-restricted CD8+ T cell epitopes, secondary 
mutations were required to compensate for fitness costs 
associated with the primary escape mutation [51, 56, 58]. 
Interestingly, the dominant HLA-B*27 epitope was unique 
in that fitness was not impaired by mutational escape; here, 
cross-reactivity of epitope-specific CD8 T cells with differ-
ent variants required multiple substitutions to achieve full 
escape [57].
Collectively, these data suggest that important qualita-
tive differences exist between CD8+ T cell responses. For 
successful immune control and containment of HCV repli-
cation, a strong and ideally broadly cross-reactive CD8+ 
T cell response associated with a high genetic barrier to 
mutational immune escape is needed. Identification of 
these epitopes requires a combined analysis of the CD8+ T 
cell immune response in concert with viral sequences.
Immunogenicity of CD8+ T cell escape variants
The clinical consequences of transmission of escape muta-
tions are largely unclear for HCV. There are studies sug-
gesting that the beneficial effect of particular HLA class I 
alleles is specific to individual HCV genotypes or even sub-
types [52, 59]. This may be attributable to sequence differ-
ences in immunodominant CD8+ T cell epitopes restricted 
by these “protective” HLA alleles. For example, the advan-
tageous effect of HLA-B*27 was so far only reported in 
HCV genotype 1 cohorts and was linked to a single epitope 
located in NS5B. Of note, the typically selected escape 
variant in genotype 1 resembles the prototype sequence in 
genotype 3. Interestingly, there is evidence that HLA-B*27 
is not protective against HCV genotype 3a, suggesting 
that preexisting substitutions in the prototype HLA-B*27-
restricted epitope precluded a dominant immune response 
[50]. Similarly, HLA-B*57 was reported to be associated 
with beneficial outcome only in cohorts infected predomi-
nantly with HCV genotype 1a [41, 52], whereas HLA-
B*57 was not protective in cohorts infected with geno-
type 1b [40]. Again, it has been highlighted that genotype 
1b typically harbors a variant of the dominant prototype 
epitope sequence in HCV genotype 1a that is associated 
with lack of the immune response [52]. Although these 
studies describe the impact of genotype or subtype-spe-
cific sequence differences on the outcome of infection, 
similar effects seem possible when it comes to transmis-
sion of escape mutations. Studies that directly address this 
are difficult to perform, because the exact viral sequence 
at the time of transmission is usually unknown. However, 
there are two large single-source outbreaks of hepatitis 
C for which the viral sequence of the inoculum is known 
and thus allow conclusions on the relevance of transmitted 
sequence variants in important CD8 T cell epitopes [9, 54]. 
In a large outbreak of HCV genotype 1b in Ireland, HLA-
A*03 and HLA-B*27 were associated with spontaneous 
immune control, whereas HLA-B*08 was associated with 
viral persistence [40]. Interestingly, in a second very sim-
ilar HCV genotype 1b outbreak in East Germany via the 
same transmission route, all three HLA alleles were neutral 
for the infection outcome [60]. This correlated with preex-
isting substitutions in the dominant epitopes presented by 
HLA-A*03 and HLA-B*27 in the source of the East-Ger-
man outbreak, whereas the dominant epitope presented by 
HLA-B*08 was prototype. Notably, the same HLA-B*08 
epitope carried substitutions in the source of the Irish out-
break possibly explaining the disadvantageous effect of 
HLA-B*08 specific for this cohort [54]. Although not con-
clusive, this strongly suggests that transmission of CD8 
T cell escape variants is disadvantageous for the clinical 
outcome of a recipient who carries the same HLA alleles. 
Mutational escape of class I epitopes may also be an issue 
in the unique setting of pregnancy, where as noted above, 
some escape mutations can revert to wild-type sequence 
and cause an increase in viral fitness for replication [55]. It 
appears that the more fit viruses are transmitted vertically 
to infants, but more study is required to define the influence 
of maternal and paternal HLA haplotype on virus evolution 
and replication in this special population.
CD8 T cell responses against variant epitopes after 
mutational escape have only been reported in individual 
cases [16, 17]. It is unclear whether T cells with the rel-
evant TCR are missing, whether they are anergic once 
chronic infection was established in the liver, or whether 
they are activated, but below the detection limit in the 
peripheral blood. Lack of T cells reactive with an escape 
variant of an HLA-A*02-restricted CD8 T cell epitope in 
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NS3 was demonstrated [61]. In a study that analyzed CD8 
T cell cross-reactivity between HCV genotype 1 and 3, an 
HLA-B*13-restricted epitope was identified that differed in 
one amino acid position [62]. Interestingly, in a cohort of 
people who inject drugs frequently exposed to genotype 1 
and 3, co-existence of two distinct CD8 T cell populations 
against both genotypes, each without cross-reactivity, was 
reproducibly observed [62]. Although here the sequence 
differences were not the consequence of mutational escape, 
this suggests that a second CD8 T cell response against a 
closely related sequence variant can be activated also in 
HCV. Further studies are needed to address, whether and to 
what extent priming and activation of CD8 T cells directed 
against escape variants of HCV epitopes is possible during 
chronic infection.
Impact of mutational escape on CD8+ T cell function 
and capacity for immune restoration
The number of epitopes that acquire escape mutations is 
variable, but 50 % or more do remain intact through the 
chronic phase of infection even though cognate CD8+ T 
cells survive in the liver. Exhaustion, characterized by a 
progressive loss of effector functions when continuously 
stimulated with antigen, almost certainly accounts for fail-
ure of these CD8+ T cells to control HCV replication [63]. 
Exhaustion is associated with increased expression of mul-
tiple inhibitory receptors such as PD-1, Tim-3, CTLA-4, 
2B4 and LAG-3 and reduced expression of CD127 and the 
IL7 receptor-alpha chain that is required for self-renewal of 
memory populations [64–70]. Interestingly, this exhausted 
phenotype changes when escape mutations are introduced 
into class I-restricted epitopes (Fig. 1). HCV-specific 
CD8+ T cells targeting escaped epitopes display less PD-1 
and more CD127 [64, 71, 72]. Moreover, proliferation is 
more robust upon antigen stimulation and they appear to 
retain or regain effector functions [64] when compared 
with CD8+ T cells with an exhausted phenotype that target 
intact epitopes. CD8+ T cells with a less exhausted phe-
notype also have an enhanced capacity to suppress HCV 
replication in a cell co-culture model after stimulation with 
a variety of cytokines or blockade of the PD-1 signaling 
pathway [73].
These observations suggest that immunotherapeutic vac-
cination or blockade of co-inhibitory signaling pathways 
may be more likely to reverse exhaustion of CD8+ T cells 
that target escaped versus intact class I epitopes. Studies 
in humans and chimpanzees suggest that both approaches 
can mobilize HCV-specific T cells and reduce virus load 
in a subset of chronically infected patients. For instance, 
reduction of virus load in a subset of patients after vaccina-
tion with a poxvirus vaccine that expressed non-structural 
HCV proteins has been reported [74]. Antibody-mediated 
blockade of the PD-1 co-inhibitory signaling pathway was 
also undertaken in humans [75] and chimpanzees [76], but 
again reduction of virus load was achieved only in a small 
subset of those who were treated. Of ten humans treated 
with a single high dose of anti-PD-1 antibodies (10 mg/
kg BW), three had a remarkable reduction in HCV RNA in 
plasma of at least 10,000-fold which remained persistently 
undetectable in one of them after treatment. Of note, one 
patient with grade 4 ALT elevation (>10× upper limit of 
normal range) also had a significant decline in viral load. 
One chimpanzee of three treated with 5 weekly doses of 
anti-PD-1 antibodies (3 mg/kg BW) showed a substantial 
reduction in viremia that reverted to baseline levels with 
discontinuation of therapy [76]. The responder showed 
robust post-treatment expansion of intrahepatic HCV-
specific CD4+ and CD8+ T cells when compared with 
the two non-responder animals [76]. Better characteriza-
tion of the T cell response and viral sequences from the 
treated patients will be required to determine why many 
of those treated with the therapeutic poxvirus vaccine 
or anti-PD-1 antibodies failed to respond. Whether they 
had a more exhausted phenotype or primarily targeted 
Fig. 1  Impact of mutational 
antigen escape on the phenotype 
of specific CD8+ T cells during 
chronic HCV infection. Con-
tinuous antigen stimulation of 
CD8+ T cells results in T cell 
exhaustion associated with poor 
antiviral function. In contrast, 
after mutational escape CD8+ 
T cells develop a “memory” 
phenotype (CD127 high) with 
high proliferative potential upon 
stimulation with the cognate 
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epitopes that had acquired escape mutations remains to be 
determined. Although even after mutational escape of the 
epitope CD8 T cells may partially contribute to viral con-
tainment [55], it seems unlikely that activation and expan-
sion of these CD8+ T cells is sufficient for viral eradica-
tion when the targeted antigen is not intact.
Do escape mutations matter for prevention or 
treatment of chronic infection?
With the rapid development of type I interferon-free direct-
acting antiviral agents against HCV, immunotherapeutic 
vaccination and/or blockade of co-inhibitory signaling 
pathways are unlikely to be considered for treatment of 
chronic hepatitis C. However, there is consensus that a pro-
phylactic vaccine will be needed to prevent HCV infection 
in groups at high risk of infection [77, 78], and perhaps as 
importantly to prevent reinfection after expensive DAA-
mediated cure of chronic hepatitis C [79]. One study in a 
chimpanzee cured of chronic infection with DAA revealed 
a substantial difference in responsiveness of T cells to 
escaped and intact epitopes upon reinfection with HCV 
2 years later [80]. Only CD8+ T cells targeting epitopes 
that had escaped during the first infection expanded in liver 
upon reinfection. They provided transient control of virus 
replication that ultimately failed as viruses with new escape 
mutations in the dominant epitopes rapidly emerged. These 
observations, although very preliminary and restricted to 
a single treated individual, suggest that escape mutations 
can skew T cell responsiveness long after cure of infection. 
Vaccination after cure may be required to either restore 
CD8+ T cell responses to epitopes that were intact or to 
broaden the repertoire to new epitopes.
For HBV, direct-acting antivirals only suppress rep-
lication of the viral genome, usually without a signifi-
cant impact on production of viral proteins thought to be 
responsible for T cell exhaustion. There is renewed inter-
est in immunotherapy to reverse the immune tolerant state 
and reduce the risk of serious long-term liver diseases. 
Combination therapies to reduce production of viral anti-
gens that exhaust T cells, and at the same time restore their 
function by vaccination or blockade of co-inhibitory sign-
aling, are receiving attention. The promise of combination 
therapy using these approaches was elegantly demonstrated 
by Roggendorf and colleagues in the woodchuck model of 
persistent HBV infection [81, 82]. These findings almost 
certainly herald the start of a new era of therapy for chronic 
hepatitis B, a disease that affects more than 240 million 
people globally. Importantly, escape mutations in class I 
epitopes have been described in patients with chronic hep-
atitis B [83], but whether they are important for CD8+ T 
cell evasion or alter the course of infection is very poorly 
understood when compared with HIV and HCV infection. 
Translation of very promising new therapies from animals 
to humans would likely benefit from a more detailed under-
standing of how escape mutations influence the repertoire, 
phenotype and function of CD8+ T cells in humans persis-
tently infected with HBV.
Conflict of interest The authors declare that they have no conflicts 
of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, 
Chien DY, Houghton M, Parham P, Walker CM (1999) Analysis 
of a successful immune response against hepatitis C virus. Immu-
nity 10(4):439–449
 2. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, 
Sidney J, McKinney D, Sette A, Hughes AL, Walker CM (2001) 
The outcome of hepatitis C virus infection is predicted by escape 
mutations in epitopes targeted by cytotoxic T lymphocytes. 
Immunity 15(6):883–895
 3. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas 
M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J, Gandhi 
RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM 
(2004) CD8 epitope escape and reversion in acute HCV infection. 
J Exp Med 200(12):1593–1604
 4. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewin-
sohn DM, Tavis JE, Rosen HR (2005) Immune evasion versus 
recovery after acute hepatitis C virus infection from a shared 
source. J Exp Med 201(11):1725–1731
 5. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sid-
ney J, Sette A, Pardoll D, Thomas DL, Ray SC (2005) Cellular 
immune selection with hepatitis C virus persistence in humans. J 
Exp Med 201(11):1741–1752
 6. Kuntzen T, Timm J, Berical A, Lewis-Ximenez LL, Jones A, 
Nolan B, Schulze zur Wiesch J, Li B, Schneidewind A, Kim AY, 
Chung RT, Lauer GM, Allen TM (2007) Viral sequence evolution 
in acute hepatitis C virus infection. J Virol 81(21):11658–11668
 7. Pfafferott K, Gaudieri S, Ulsenheimer A, James I, Heeg M, Nolan 
D, John M, Rauch A, Mallal S, Lucas A, Klenerman P, Diepol-
der HM, Lucas M (2011) Constrained pattern of viral evolution 
in acute and early HCV infection limits viral plasticity. PLoS One 
6(2):e16797
 8. Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, 
Rauch A, di Iulio J, John M, Lucas M, Fitzmaurice K, McKi-
ernan S, Norris S, Kelleher D, Klenerman P, Gaudieri S (2011) 
Effect of immune pressure on hepatitis C virus evolution: insights 
from a single-source outbreak. Hepatology 53(2):396–405
 9. Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann-Haefe-
lin C, Chang DI, Klein M, Heinemann FM, Tenckhoff H, Wiese 
M, Horn PA, Viazov S, Spengler U, Roggendorf M, Scherbaum 
N, Nattermann J, Hoffmann D, Timm J, East German HCVSG 
(2011) CD8+ T-cell response promotes evolution of hepatitis C 
virus nonstructural proteins. Gastroenterology 140(7):2064–2073
 10. Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier 
R, Kuntzen T, Fischer W, Nolan BE, Duncan J, Schulze zur 
Wiesch J, Kim AY, Frahm N, Brander C, Chung RT, Lauer GM, 
35Med Microbiol Immunol (2015) 204:29–38 
1 3
Korber BT, Allen TM (2007) Human leukocyte antigen-associ-
ated sequence polymorphisms in hepatitis C virus reveal repro-
ducible immune responses and constraints on viral evolution. 
Hepatology 46(2):339–349
 11. Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey 
G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay 
M, Weber R, Telenti A, Furrer H, James I, Lucas M, Mallal SA 
(2006) Evidence of viral adaptation to HLA class I-restricted 
immune pressure in chronic hepatitis C virus infection. J Virol 
80(22):11094–11104
 12. Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng 
W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker 
R, Freitas E, Humphreys I, Furrer H, Gunthard HF, Hirschel B, 
Mallal S, John M, Lucas M, Barnes E, Gaudieri S (2009) Diver-
gent adaptation of hepatitis C virus genotypes 1 and 3 to human 
leukocyte antigen-restricted immune pressure. Hepatology 
50(4):1017–1029
 13. Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum 
S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, 
Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J (2008) 
Analysis of the evolutionary forces in an immunodominant 
CD8 epitope in hepatitis C virus at a population level. J Virol 
82(7):3438–3451
 14. Callendret B, Bukh J, Eccleston HB, Heksch R, Hasselschwert 
DL, Purcell RH, Hughes AL, Walker CM (2011) Transmission 
of clonal hepatitis C virus genomes reveals the dominant but 
transitory role of CD8+ T cells in early viral evolution. J Virol 
85(22):11833–11845
 15. Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, Rice 
CM, Feinstone SM, Major ME (2004) Long-term persistence of 
infection in chimpanzees inoculated with an infectious hepati-
tis C virus clone is associated with a decrease in the viral amino 
acid substitution rate and low levels of heterogeneity. J Virol 
78(18):9782–9789
 16. Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Han-
son HL, Rice CM, Walker CM, Grakoui A (2008) Stable cyto-
toxic T cell escape mutation in hepatitis C virus is linked to main-
tenance of viral fitness. PLoS Pathog 4(9):e1000143
 17. Salloum S, Oniangue-Ndza C, Neumann-Haefelin C, Hudson 
L, Giugliano S, aus dem Siepen M, Nattermann J, Spengler U, 
Lauer GM, Wiese M, Klenerman P, Bright H, Scherbaum N, 
Thimme R, Roggendorf M, Viazov S, Timm J (2008) Escape 
from HLA-B*08-restricted CD8 T cells by hepatitis C virus is 
associated with fitness costs. J Virol 82(23):11803–11812
 18. Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray 
SC (2005) Comprehensive analyses of CD8+ T cell responses 
during longitudinal study of acute human hepatitis C. Hepatology 
42(1):104–112
 19. Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, 
Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, 
Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, 
Altfeld M (2005) De novo generation of escape variant-specific 
CD8+ T-cell responses following cytotoxic T-lymphocyte escape 
in chronic human immunodeficiency virus type 1 infection. J 
Virol 79(20):12952–12960
 20. Roider J, Kalteis AL, Vollbrecht T, Gloning L, Stirner R, Hen-
rich N, Bogner JR, Draenert R (2013) Adaptation of CD8 T cell 
responses to changing HIV-1 sequences in a cohort of HIV-1 
infected individuals not selected for a certain HLA allele. PLoS 
One 8(12):e80045
 21. Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, 
Trocha A, Yu XG, Verrill C, Allen T, Moore C, Mallal S, Bur-
chett S, McIntosh K, Pelton SI, St John MA, Hazra R, Klenerman 
P, Altfeld M, Walker BD, Goulder PJ (2005) HIV-1 viral escape 
in infancy followed by emergence of a variant-specific CTL 
response. J Immunol 174(12):7524–7530
 22. O’Connell KA, Hegarty RW, Siliciano RF, Blankson JN (2011) 
Viral suppression of multiple escape mutants by de novo CD8(+) 
T cell responses in a human immunodeficiency virus-1 infected 
elite suppressor. Retrovirology 8:63
 23. Bailey JR, Williams TM, Siliciano RF, Blankson JN (2006) 
Maintenance of viral suppression in HIV-1-infected HLA-
B*57 + elite suppressors despite CTL escape mutations. J Exp 
Med 203(5):1357–1369
 24. Ladell K, Hashimoto M, Iglesias MC, Wilmann PG, McLaren JE, 
Gras S, Chikata T, Kuse N, Fastenackels S, Gostick E, Bridgeman 
JS, Venturi V, Arkoub ZA, Agut H, van Bockel DJ, Almeida JR, 
Douek DC, Meyer L, Venet A, Takiguchi M, Rossjohn J, Price 
DA, Appay V (2013) A molecular basis for the control of preim-
mune escape variants by HIV-specific CD8+ T cells. Immunity 
38(3):425–436
 25. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston 
MN, Burgett N, Swartz ME, Yang A, Alter G, Yu XG, Meier A, 
Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington 
M, Walker BD (2006) HLA alleles associated with delayed pro-
gression to AIDS contribute strongly to the initial CD8+ T cell 
response against HIV-1. PLoS Med 3(10):e403
 26. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht 
FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins 
GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy 
JA, Mullins JI, Walker BD (2001) Cellular immune responses and 
viral diversity in individuals treated during acute and early HIV-1 
infection. J Exp Med 193(2):169–180
 27. Klenerman P, Zinkernagel RM (1998) Original antigenic sin 
impairs cytotoxic T lymphocyte responses to viruses bearing var-
iant epitopes. Nature 394(6692):482–485
 28. Zehn D, Turner MJ, Lefrancois L, Bevan MJ (2010) Lack of 
original antigenic sin in recall CD8+ T cell responses. J Immunol 
184(11):6320–6326
 29. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprow-
icz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen TM, Lohse 
AW, McGovern B, Chung RT, Kwok WW, Kim AY, Lauer GM 
(2012) Broadly directed virus-specific CD4+ T cell responses 
are primed during acute hepatitis C infection, but rapidly dis-
appear from human blood with viral persistence. J Exp Med 
209(1):61–75
 30. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, 
Ghrayeb J, Murthy KK, Rice CM, Walker CM (2003) HCV per-
sistence and immune evasion in the absence of memory T cell 
help. Science 302(5645):659–662
 31. Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker 
BD, Ndung’u T, Shapiro R, Frater J, Brumme ZL, Goulder 
PJ, Heckerman D (2012) Widespread impact of HLA restric-
tion on immune control and escape pathways of HIV-1. J Virol 
86(9):5230–5243
 32. Bronke C, Almeida CA, McKinnon E, Roberts SG, Keane NM, 
Chopra A, Carlson JM, Heckerman D, Mallal S, John M (2013) 
HIV escape mutations occur preferentially at HLA-binding sites 
of CD8 T-cell epitopes. Aids 27(6):899–905
 33. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, 
Hartman K, Shintani AK, Walker CM, Kalams SA (2004) Lim-
ited T cell receptor diversity of HCV-specific T cell responses is 
associated with CTL escape. J Exp Med 200(3):307–319
 34. Kimura Y, Gushima T, Rawale S, Kaumaya P, Walker CM (2005) 
Escape mutations alter proteasome processing of major histo-
compatibility complex class I-restricted epitopes in persistent 
hepatitis C virus infection. J Virol 79(8):4870–4876
 35. Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wede-
meyer H, Ruppert T, Rispeter K, Henklein P, Sijts A, Hengel 
H, Kloetzel PM, Rehermann B (2004) Hepatitis C virus muta-
tion affects proteasomal epitope processing. J Clin Investig 
114(2):250–259
36 Med Microbiol Immunol (2015) 204:29–38
1 3
 36. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak 
MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael 
AJ, Rowland-Jones S (1997) Late escape from an immunodomi-
nant cytotoxic T-lymphocyte response associated with progres-
sion to AIDS. Nat Med 3(2):212–217
 37. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo 
MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, 
He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIn-
tosh K, Korber BT, Walker BD (2001) Evolution and transmis-
sion of stable CTL escape mutations in HIV infection. Nature 
412(6844):334–338
 38. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado 
JG, Tang J, Farmer P, Ndung’u T, Lakhi S, Gilmour J, Goepfert 
P, Walker BD, Kaslow R, Mulenga J, Allen S, Goulder PJ, Hunter 
E (2009) Evolution of HLA-B*5703 HIV-1 escape mutations in 
HLA-B*5703-positive individuals and their transmission recipi-
ents. J Exp Med 206(4):909–921
 39. International HIVCS, Pereyra F, Jia X, McLaren PJ, Telenti A, 
de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, Car-
rington M, Kadie CM, Carlson JM, Heckerman D, Graham RR, 
Plenge RM, Deeks SG, Gianniny L, Crawford G, Sullivan J, 
Gonzalez E, Davies L, Camargo A, Moore JM, Beattie N, Gupta 
S, Crenshaw A, Burtt NP, Guiducci C, Gupta N, Gao X, Qi Y, 
Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss KL, 
Lemay P, O’Leary J, Schaefer T, Verma P, Toth I, Block B, Baker 
B, Rothchild A, Lian J, Proudfoot J, Alvino DM, Vine S, Addo 
MM, Allen TM, Altfeld M, Henn MR, Le Gall S, Streeck H, Haas 
DW, Kuritzkes DR, Robbins GK, Shafer RW, Gulick RM, Shi-
kuma CM, Haubrich R, Riddler S, Sax PE, Daar ES, Ribaudo HJ, 
Agan B, Agarwal S, Ahern RL, Allen BL, Altidor S, Altschuler 
EL, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady 
U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak 
J, Barton S, Basden P, Basgoz N, Bazner S, Bellos NC, Ben-
son AM, Berger J, Bernard NF, Bernard AM, Birch C, Bodner 
SJ, Bolan RK, Boudreaux ET, Bradley M, Braun JF, Brndjar JE, 
Brown SJ, Brown K, Brown ST, Burack J, Bush LM, Cafaro V, 
Campbell O, Campbell J, Carlson RH, Carmichael JK, Casey 
KK, Cavacuiti C, Celestin G, Chambers ST, Chez N, Chirch LM, 
Cimoch PJ, Cohen D, Cohn LE, Conway B, Cooper DA, Cor-
nelson B, Cox DT, Cristofano MV, Cuchural G Jr, Czartoski JL, 
Dahman JM, Daly JS, Davis BT, Davis K, Davod SM, DeJesus 
E, Dietz CA, Dunham E, Dunn ME, Ellerin TB, Eron JJ, Fang-
man JJ, Farel CE, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel 
R, Freedberg KA, French NK, Fuchs JD, Fuller JD, Gaberman 
J, Gallant JE, Gandhi RT, Garcia E, Garmon D, Gathe JC Jr, 
Gaultier CR, Gebre W, Gilman FD, Gilson I, Goepfert PA, Got-
tlieb MS, Goulston C, Groger RK, Gurley TD, Haber S, Hard-
wicke R, Hardy WD, Harrigan PR, Hawkins TN, Heath S, Hecht 
FM, Henry WK, Hladek M, Hoffman RP, Horton JM, Hsu RK, 
Huhn GD, Hunt P, Hupert MJ, Illeman ML, Jaeger H, Jellinger 
RM, John M, Johnson JA, Johnson KL, Johnson H, Johnson K, 
Joly J, Jordan WC, Kauffman CA, Khanlou H, Killian RK, Kim 
AY, Kim DD, Kinder CA, Kirchner JT, Kogelman L, Kojic EM, 
Korthuis PT, Kurisu W, Kwon DS, LaMar M, Lampiris H, Lan-
zafame M, Lederman MM, Lee DM, Lee JM, Lee MJ, Lee ET, 
Lemoine J, Levy JA, Llibre JM, Liguori MA, Little SJ, Liu AY, 
Lopez AJ, Loutfy MR, Loy D, Mohammed DY, Man A, Mansour 
MK, Marconi VC, Markowitz M, Marques R, Martin JN, Mar-
tin HL Jr, Mayer KH, McElrath MJ, McGhee TA, McGovern 
BH, McGowan K, McIntyre D, McLeod GX, Menezes P, Mesa 
G, Metroka CE, Meyer-Olson D, Miller AO, Montgomery K, 
Mounzer KC, Nagami EH, Nagin I, Nahass RG, Nelson MO, 
Nielsen C, Norene DL, O’Connor DH, Ojikutu BO, Okulicz J, 
Oladehin OO, Oldfield EC 3rd, Olender SA, Ostrowski M, Owen 
WF Jr, Pae E, Parsonnet J, Pavlatos AM, Perlmutter AM, Pierce 
MN, Pincus JM, Pisani L, Price LJ, Proia L, Prokesch RC, Pujet 
HC, Ramgopal M, Rathod A, Rausch M, Ravishankar J, Rhame 
FS, Richards CS, Richman DD, Rodes B, Rodriguez M, Rose 
RC 3rd, Rosenberg ES, Rosenthal D, Ross PE, Rubin DS, Rum-
baugh E, Saenz L, Salvaggio MR, Sanchez WC, Sanjana VM, 
Santiago S, Schmidt W, Schuitemaker H, Sestak PM, Shalit P, 
Shay W, Shirvani VN, Silebi VI, Sizemore JM Jr, Skolnik PR, 
Sokol-Anderson M, Sosman JM, Stabile P, Stapleton JT, Starrett 
S, Stein F, Stellbrink HJ, Sterman FL, Stone VE, Stone DR, Tam-
bussi G, Taplitz RA, Tedaldi EM, Telenti A, Theisen W, Torres R, 
Tosiello L, Tremblay C, Tribble MA, Trinh PD, Tsao A, Ueda P, 
Vaccaro A, Valadas E, Vanig TJ, Vecino I, Vega VM, Veikley W, 
Wade BH, Walworth C, Wanidworanun C, Ward DJ, Warner DA, 
Weber RD, Webster D, Weis S, Wheeler DA, White DJ, Wilkins 
E, Winston A, Wlodaver CG, van’t Wout A, Wright DP, Yang 
OO, Yurdin DL, Zabukovic BW, Zachary KC, Zeeman B, Zhao 
M (2010) The major genetic determinants of HIV-1 control affect 
HLA class I peptide presentation. Science 330(6010):1551–1557
 40. McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, 
Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D (2004) Dis-
tinct MHC class I and II alleles are associated with hepatitis C 
viral clearance, originating from a single source. Hepatology 
40(1):108–114
 41. Thio CL, Gao X, Goedert JJ, Vlahov D, Nelson KE, Hilgartner 
MW, O’Brien SJ, Karacki P, Astemborski J, Carrington M, 
Thomas DL (2002) HLA-Cw*04 and hepatitis C virus persis-
tence. J Virol 76(10):4792–4797
 42. Hraber P, Kuiken C, Yusim K (2007) Evidence for human leu-
kocyte antigen heterozygote advantage against hepatitis C virus 
infection. Hepatology 46(6):1713–1721
 43. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, Conlon 
C, Workman C, Shaunak S, Olson K, Goulder P, Brander C, Ogg 
G, Sullivan JS, Dyer W, Jones I, McMichael AJ, Rowland-Jones 
S, Phillips RE (2001) Clustered mutations in HIV-1 gag are con-
sistently required for escape from HLA-B27-restricted cytotoxic 
T lymphocyte responses. J Exp Med 193(3):375–386
 44. Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra 
F, Rathod A, Block BL, Brumme ZL, Brumme CJ, Baker B, 
Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, 
Toth I, Arts EJ, Allen TM, Walker BD (2009) HLA-B57/B*5801 
human immunodeficiency virus type 1 elite controllers select 
for rare gag variants associated with reduced viral replication 
capacity and strong cytotoxic T-lymphocyte recognition. J Virol 
83(6):2743–2755
 45. Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F, 
Block BL, Trocha A, John M, Mallal S, Harrigan PR, Walker 
BD (2009) HLA-associated viral mutations are common in 
human immunodeficiency virus type 1 elite controllers. J Virol 
83(7):3407–3412
 46. Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, 
Rosato PC, Kadie CM, Carlson JM, Markle TJ, Streeck H, Kelle-
her AD, Markowitz M, Jessen H, Rosenberg E, Altfeld M, Har-
rigan PR, Heckerman D, Walker BD, Allen TM (2010) Early 
selection in Gag by protective HLA alleles contributes to reduced 
HIV-1 replication capacity that may be largely compensated for 
in chronic infection. J Virol 84(22):11937–11949
 47. Goepfert PA, Lumm W, Farmer P, Matthews P, Prendergast A, 
Carlson JM, Derdeyn CA, Tang J, Kaslow RA, Bansal A, Yusim 
K, Heckerman D, Mulenga J, Allen S, Goulder PJ, Hunter E 
(2008) Transmission of HIV-1 Gag immune escape mutations is 
associated with reduced viral load in linked recipients. J Exp Med 
205(5):1009–1017
 48. Altfeld M, Allen TM (2006) Hitting HIV where it hurts: an 
alternative approach to HIV vaccine design. Trends Immunol 
27(11):504–510
 49. Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko 
S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, 
37Med Microbiol Immunol (2015) 204:29–38 
1 3
Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra 
F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD 
(2012) TCR clonotypes modulate the protective effect of HLA 
class I molecules in HIV-1 infection. Nat Immunol 13(7):691–700
 50. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangen-
berg HC, Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus 
O, von Weizsacker F, Roggendorf M, Kelleher D, Klenerman P, 
Blum HE, Thimme R (2006) Dominant influence of an HLA-B27 
restricted CD8+ T cell response in mediating HCV clearance and 
evolution. Hepatology 43(3):563–572
 51. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani 
S, Gaudieri S, Sims S, Dempsey E, Freitas E, Lea S, McKiernan 
S, Norris S, Long A, Kelleher D, Klenerman P (2011) Molecular 
footprints reveal the impact of the protective HLA-A*03 allele in 
hepatitis C virus infection. Gut 60(11):1563–1571
 52. Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, 
Berical AC, Feller AJ, Johnson KL, Schulze zur Wiesch J, Rob-
bins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer 
GM (2011) Spontaneous control of HCV is associated with 
expression of HLA-B 57 and preservation of targeted epitopes. 
Gastroenterology 140(2):686–696
 53. Ruhl M, Chhatwal P, Strathmann H, Kuntzen T, Bankwitz D, 
Skibbe K, Walker A, Heinemann FM, Horn PA, Allen TM, Hoff-
mann D, Pietschmann T, Timm J (2012) Escape from a dominant 
HLA-B*15-restricted CD8+ T cell response against hepatitis 
C virus requires compensatory mutations outside the epitope. J 
Virol 86(2):991–1000
 54. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, 
Thomas DL (2005) Divergent and convergent evolution after 
a common-source outbreak of hepatitis C virus. J Exp Med 
201(11):1753–1759
 55. Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, 
Prasad MR, Lemon SM, Grakoui A, Walker CM (2013) Loss of 
immune escape mutations during persistent HCV infection in 
pregnancy enhances replication of vertically transmitted viruses. 
Nat Med 19(11):1529–1533
 56. Neumann-Haefelin C, Oniangue-Ndza C, Kuntzen T, Schmidt 
J, Nitschke K, Sidney J, Caillet-Saguy C, Binder M, Kersting 
N, Kemper MW, Power KA, Ingber S, Reyor LL, Hills-Evans 
K, Kim AY, Lauer GM, Lohmann V, Sette A, Henn MR, Bres-
sanelli S, Thimme R, Allen TM (2011) Human leukocyte antigen 
B27 selects for rare escape mutations that significantly impair 
hepatitis C virus replication and require compensatory mutations. 
Hepatology 54(4):1157–1166
 57. Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, 
Kort J, Timm J, McKiernan S, Kelleher D, Gruener N, Tavis JE, 
Rosen HR, Shaw J, Bowness P, Blum HE, Klenerman P, Barten-
schlager R, Thimme R (2009) Loss of viral fitness and cross-rec-
ognition by CD8+ T cells limit HCV escape from a protective 
HLA-B27-restricted human immune response. J Clin Investig 
119(2):376–386
 58. Oniangue-Ndza C, Kuntzen T, Kemper M, Berical A, Wang YE, 
Neumann-Haefelin C, Foote PK, Hills-Evans K, Reyor LL, Kane 
K, Gladden AD, Bloom AK, Power KA, Thimme R, Lauer GM, 
Henn MR, Kim AY, Allen TM (2011) Compensatory mutations 
restore the replication defects caused by cytotoxic T lympho-
cyte escape mutations in hepatitis C virus polymerase. J Virol 
85(22):11883–11890
 59. Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmau-
rice K, Oniangue-Ndza C, Kemper MN, Humphreys I, McKier-
nan S, Kelleher D, Lohmann V, Bowness P, Huzly D, Rosen HR, 
Kim AY, Lauer GM, Allen TM, Barnes E, Roggendorf M, Blum 
HE, Thimme R (2010) Protective effect of human leukocyte anti-
gen B27 in hepatitis C virus infection requires the presence of a 
genotype-specific immunodominant CD8+ T-cell epitope. Hepa-
tology 51(1):54–62
 60. Ziegler S, Ruhl M, Tenckhoff H, Wiese M, Heinemann FM, Horn 
PA, Spengler U, Neumann-Haefelin C, Nattermann J, Timm J, 
East-German HCVSG (2013) Susceptibility to chronic hepatitis 
C virus infection is influenced by sequence differences in immu-
nodominant CD8+ T cell epitopes. J Hepatol 58(1):24–30
 61. Wolfl M, Rutebemberwa A, Mosbruger T, Mao Q, Li HM, Net-
ski D, Ray SC, Pardoll D, Sidney J, Sette A, Allen T, Kuntzen T, 
Kavanagh DG, Kuball J, Greenberg PD, Cox AL (2008) Hepatitis 
C virus immune escape via exploitation of a hole in the T cell 
repertoire. J Immunol 181(9):6435–6446
 62. Giugliano S, Oezkan F, Bedrejowski M, Kudla M, Reiser M, 
Viazov S, Scherbaum N, Roggendorf M, Timm J (2009) Degree 
of cross-genotype reactivity of hepatitis C virus-specific CD8+ T 
cells directed against NS3. Hepatology 50(3):707–716
 63. Wherry EJ (2011) T cell exhaustion. Nat Immunol 12(6):492–499
 64. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, 
Pircher H, Thimme R (2010) Coexpression of PD-1, 2B4, CD160 
and KLRG1 on exhausted HCV-specific CD8+ T cells is linked 
to antigen recognition and T cell differentiation. PLoS Pathog 
6(6):e1000947
 65. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson 
L, Livingston S, McMahon BJ, Castelblanco N, Kuchroo V, 
Gretch DR, Rosen HR (2009) Negative immune regulator Tim-3 
is overexpressed on T cells in hepatitis C virus infection and its 
blockade rescues dysfunctional CD4+ and CD8+ T cells. J Virol 
83(18):9122–9130
 66. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale 
G, Ferrari C (2006) PD-1 expression in acute hepatitis C virus 
(HCV) infection is associated with HCV-specific CD8 exhaus-
tion. J Virol 80(22):11398–11403
 67. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, 
Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, 
Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Gra-
koui A (2007) Liver-infiltrating lymphocytes in chronic human 
hepatitis C virus infection display an exhausted phenotype with 
high levels of PD-1 and low levels of CD127 expression. J Virol 
81(6):2545–2553
 68. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kamin-
ski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM 
(2009) Synergistic reversal of intrahepatic HCV-specific CD8 T 
cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pat-
hog 5(2):e1000313
 69. Schlaphoff V, Lunemann S, Suneetha PV, Jaroszewicz J, 
Grabowski J, Dietz J, Helfritz F, Bektas H, Sarrazin C, Manns 
MP, Cornberg M, Wedemeyer H (2011) Dual function of the NK 
cell receptor 2B4 (CD244) in the regulation of HCV-specific 
CD8+ T cells. PLoS Pathog 7(5):e1002045
 70. McMahan RH, Golden-Mason L, Nishimura MI, McMahon 
BJ, Kemper M, Allen TM, Gretch DR, Rosen HR (2010) Tim-3 
expression on PD-1+ HCV-specific human CTLs is associated 
with viral persistence, and its blockade restores hepatocyte-
directed in vitro cytotoxicity. J Clin Investig 120(12):4546–4557
 71. Kasprowicz V, Kang YH, Lucas M, Schulze zur Wiesch J, 
Kuntzen T, Fleming V, Nolan BE, Longworth S, Berical A, 
Thimme R, Lewis-Ximenez L, Allen TM, Kim AY, Klenerman 
P, Lauer GM (2010) Hepatitis C virus (HCV) sequence variation 
induces an HCV-specific T-cell phenotype analogous to spontane-
ous resolution. J Virol 84(3):1656–1663
 72. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd 
KA, Clute S, Wang C, Korman A, Sette A, Sidney J, Pardoll DM, 
Cox AL (2008) High-programmed death-1 levels on hepatitis C 
virus-specific T cells during acute infection are associated with 
viral persistence and require preservation of cognate antigen dur-
ing chronic infection. J Immunol 181(12):8215–8225
 73. Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, 
Thimme R (2013) Factors that determine the antiviral efficacy 
38 Med Microbiol Immunol (2015) 204:29–38
1 3
of HCV-specific CD8(+) T cells ex vivo. Gastroenterology 
144(2):426–436
 74. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, 
Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Trepo 
C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, 
Inchauspe G (2011) A poxvirus vaccine is safe, induces T-cell 
responses, and decreases viral load in patients with chronic hepa-
titis C. Gastroenterology 141(3):890–899
 75. Gardiner D, Lalezari J, Lawitz E, DiMicco M, Ghalib R, Reddy 
KR, Chang KM, Sulkowski M, Marro SO, Anderson J, He B, 
Kansra V, McPhee F, Wind-Rotolo M, Grasela D, Selby M, Kor-
man AJ, Lowy I (2013) A randomized, double-blind, placebo-
controlled assessment of BMS-936558, a fully human mono-
clonal antibody to programmed death-1 (PD-1), in patients with 
chronic hepatitis C virus infection. PLoS One 8(5):e63818
 76. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert 
DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, 
Ahmed R, Walker CM (2013) Immunotherapy of chronic hepa-
titis C virus infection with antibodies against programmed cell 
death-1 (PD-1). Proc Natl Acad Sci USA 110(37):15001–15006
 77. Cox AL, Thomas DL (2013) Hepatitis C virus vaccines among 
people who inject drugs. Clin Infect Dis off Publ Infect Dis Soci 
Am 57(Suppl 2):S46–S50
 78. Grebely J, Dore GJ (2014) Can hepatitis C virus infection be 
eradicated in people who inject drugs? Antivir Res 104:62–72
 79. Honegger JR, Zhou Y, Walker CM (2014) Will there be a vaccine 
to prevent HCV infection? Semin Liver Dis 34(1):79–88. doi:10.
1055/s-0034-1371081
 80. Callendret B, Eccleston HB, Hall S, Satterfield W, Capone S, Fol-
gori A, Cortese R, Nicosia A, Walker CM (2014) T-cell immunity 
and hepatitis C virus reinfection after cure of chronic hepatitis C 
with an interferon-free antiviral regimen in a chimpanzee. Hepa-
tology 60(5):1531–1540. doi:10.1002/hep.27278
 81. Kosinska AD, Zhang E, Johrden L, Liu J, Seiz PL, Zhang X, Ma 
Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, 
Roggendorf M (2013) Combination of DNA prime–adenovi-
rus boost immunization with entecavir elicits sustained control 
of chronic hepatitis B in the woodchuck model. PLoS Pathog 
9(6):e1003391
 82. Liu J, Zhang E, Ma Z, Wu W, Kosinska A, Zhang X, Moller I, 
Seiz P, Glebe D, Wang B, Yang D, Lu M, Roggendorf M (2014) 
Enhancing virus-specific immunity in vivo by combining thera-
peutic vaccination and PD-L1 blockade in chronic hepadnaviral 
infection. PLoS Pathog 10(1):e1003856
 83. Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette 
A, Penna A, Giuberti T, Fiaccadori F, Ferrari C (1994) Cytotoxic 
T lymphocyte response to a wild type hepatitis B virus epitope in 
patients chronically infected by variant viruses carrying substitu-
tions within the epitope. J Exp Med 180(3):933–943
